🚀 VC round data is live in beta, check it out!
Genus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genus and similar public comparables like BGI Genomics, Andersons, Insight Lifetech, FMC and more.
Genus Overview
About Genus
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
Founded
1994
HQ
Employees
3.3K
Website
Financials (LTM)
EV
$3B
Genus Financials
Genus reported last 12-month revenue of $920M and EBITDA of $182M.
In the same LTM period, Genus generated $442M in gross profit, $182M in EBITDA, and $88M in net income.
Revenue (LTM)
Genus P&L
In the most recent fiscal year, Genus reported revenue of $910M and EBITDA of $163M.
Genus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $920M | XXX | $910M | XXX | XXX | XXX |
| Gross Profit | $442M | XXX | $276M | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $182M | XXX | $163M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $88M | XXX | $72M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $231M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genus Stock Performance
Genus has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
Genus' stock price is $35.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | -1.0% | XXX | XXX | XXX | $1.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenus Valuation Multiples
Genus trades at 2.9x EV/Revenue multiple, and 14.7x EV/EBITDA.
EV / Revenue (LTM)
Genus Financial Valuation Multiples
As of April 18, 2026, Genus has market cap of $2B and EV of $3B.
Equity research analysts estimate Genus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genus has a P/E ratio of 27.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 14.7x | XXX | 16.4x | XXX | XXX | XXX |
| EV/EBIT | 20.3x | XXX | 23.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | 9.7x | XXX | XXX | XXX |
| P/E | 27.0x | XXX | 32.8x | XXX | XXX | XXX |
| EV/FCF | 37.5x | XXX | 40.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genus Margins & Growth Rates
Genus' revenue in the last 12 month grew by 2%.
Genus' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Genus' rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genus' rule of X is 25% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Genus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genus Public Comps
See public comps and valuation multiples for other Agriculture and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| BGI Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Andersons | XXX | XXX | XXX | XXX | XXX | XXX |
| Insight Lifetech | XXX | XXX | XXX | XXX | XXX | XXX |
| FMC | XXX | XXX | XXX | XXX | XXX | XXX |
| GRAIL | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genus M&A Activity
Genus acquired XXX companies to date.
Last acquisition by Genus was on XXXXXXXX, XXXXX. Genus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenus Investment Activity
Genus invested in XXX companies to date.
Genus made its latest investment on XXXXXXXX, XXXXX. Genus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genus
| When was Genus founded? | Genus was founded in 1994. |
| Where is Genus headquartered? | Genus is headquartered in United Kingdom. |
| How many employees does Genus have? | As of today, Genus has over 3K employees. |
| Who is the CEO of Genus? | Genus' CEO is Jorgen Kokke. |
| Is Genus publicly listed? | Yes, Genus is a public company listed on London Stock Exchange. |
| What is the stock symbol of Genus? | Genus trades under GNS ticker. |
| When did Genus go public? | Genus went public in 2000. |
| Who are competitors of Genus? | Genus main competitors are BGI Genomics, Andersons, Insight Lifetech, FMC. |
| What is the current market cap of Genus? | Genus' current market cap is $2B. |
| What is the current revenue of Genus? | Genus' last 12 months revenue is $920M. |
| What is the current revenue growth of Genus? | Genus revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Genus? | Current revenue multiple of Genus is 2.9x. |
| Is Genus profitable? | Yes, Genus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genus? | Genus' last 12 months EBITDA is $182M. |
| What is Genus' EBITDA margin? | Genus' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Genus? | Current EBITDA multiple of Genus is 14.7x. |
| What is the current FCF of Genus? | Genus' last 12 months FCF is $71M. |
| What is Genus' FCF margin? | Genus' last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Genus? | Current FCF multiple of Genus is 37.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.